PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Actinic keratosis

Drugs in development · updated 30 October 2026

Actinic keratosis: drugs in development

As of 30 October 2026 there are 9 active clinical trials (recruiting or ongoing, phases I–III) on 8 drugs for actinic keratosis. 3 are experimental, that is not yet approved in the United States.

9Active trials
3Experimental drugs
1Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
CryotherapyIII1NCT07273656
HW211026II2NCT07513454
15% Aluminum Chloride HexahydrateI1NCT07401277

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
ImiquimodZyclara®, Aldara®III1NCT05212246
TirbanibulinKlisyri®III1NCT07273656
CalcipotrieneCalcipotriol, Sorilux®II2NCT05699603
Fluorouracil5-Fluorouracil, AdrucilII2NCT05699603
ImipramineJanimine®, Tofranil-Pm®II2NCT06778434

Sorted by most advanced phase and number of active trials.

All 8 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D055623 “Keratosis, Actinic”.

ItalianoFrançaisDeutsch